GlassScriptPhysician profile
Bassam Malo
NPI 1205148293
$163,726.59
in general payments reported to CMS, 2019-2025
21 companies · $58K in 2025
The $58K reported for 2025 was more than what 97% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $559 · 2022: $7,921 · 2023: $42K · 2024: $55K · 2025: $58K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $111K · Consulting Fee: $25K · Travel and Lodging: $13K · Food and Beverage: $6,306 · Education: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $110,610.50 |
| Consulting Fee | $24,819.00 |
| Travel and Lodging | $13,376.10 |
| Food and Beverage | $6,306.09 |
| Education | $134.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $64,476.43 | 2023-2025 | Rystiggo, Zilbrysq |
| Genzyme Corporation | $48,212.20 | 2022-2024 | |
| Amgen INC. | $21,096.63 | 2024-2025 | Uplizna |
| Argenx US, INC. | $13,163.69 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Janssen Biotech, INC. | $8,231.30 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $3,175.83 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $2,165.00 | 2023 | |
| Abbvie INC. | $1,137.57 | 2021-2024 | |
| Mdd US Operations, LLC | $500.00 | 2023 | Apokyn |
| Sk Life Science, INC. | $361.62 | 2022-2024 | Xcopri |
| Alexion Pharmaceuticals, INC. | $166.88 | 2023-2024 | Ultomiris |
| Janssen Global Services, LLC | $142.66 | 2023 | |
| Nevro Corp. | $138.67 | 2022 | |
| Globus Medical, INC. | $132.06 | 2025 | Senza |
| Biogen, INC. | $117.62 | 2023 | Spinraza |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $112.22 | 2024 | |
| Lilly USA, LLC | $111.32 | 2025 | |
| Amicus Therapeutics, INC. | $101.39 | 2023-2025 | Opfolda, Pombiliti |
| Janssen Pharmaceuticals, INC | $89.99 | 2022 | |
| Pfizer INC. | $65.04 | 2022-2025 | |
| Tanabe Pharma America, INC. | $28.47 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bassam Malo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.